Co-Diagnostics Signs Exclusive Distribution Agreement with Partner in Mexico
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2026
0mins
Co-Diagnostics has entered into an exclusive distribution agreement with its partner in Mexico for the Co-Dx PCR point-of-care platform, including the PCR Pro instrument and associated test kits, advancing the company's strategy to expand its commercialization network and footprint in Latin America ahead of the platform's market launch, which remains subject to applicable regulatory review and authorization. The company has generated over $18M in revenue through sales of its Logix Smart PCR tests and clinical lab testing equipment since 2020 with this distribution partner. The previously existing partnership was also instrumental in driving adoption of the company's Logix Smart COVID-19 PCR test, which comprised more than 50% of all COVID-19 tests used across Mexico through 2021, according to publicly available data of COVID tests performed during that period.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CODX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CODX
Wall Street analysts forecast CODX stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 3.330
Low
1.50
Averages
1.50
High
1.50
Current: 3.330
Low
1.50
Averages
1.50
High
1.50
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Co-Diagnostics Advances Technology Transfer with CoMira Partnership
- Technology Transfer Initiative: Co-Diagnostics' delegation from CoMira Diagnostics visited the Salt Lake City headquarters, marking a new phase in the planned technology transfer that is expected to enhance diagnostic test production capabilities in Saudi Arabia and 18 other Middle Eastern and North African countries.
- Automated Production Line Unveiling: During the visit, Co-Diagnostics unveiled its future automated PCR test kit manufacturing line, a critical facility that will support rapid scaling of diagnostic test production to meet local healthcare needs and improve operational efficiency.
- Significance of International Collaboration: CEO Dwight Egan emphasized that the partnership with CoMira reflects the belief that closing the diagnostics gap requires a blend of cutting-edge technology and local expertise, aiming to enhance diagnostic accessibility across the region.
- AI-Integrated Platform: The Co-Dx PCR platform integrates artificial intelligence and cloud-connected outbreak surveillance capabilities, which are expected to be part of the CoMira partnership, reflecting the company's strategic intent to deploy automated, AI-driven diagnostic infrastructure in key international markets.
See More
Co-Diagnostics Advances Technology Transfer with CoMira Partnership
- Technology Transfer Initiative: Co-Diagnostics is set to transfer its molecular diagnostics platform and manufacturing capabilities to CoMira Diagnostics in Saudi Arabia, which is expected to significantly enhance diagnostic test production capacity in the region to meet healthcare needs.
- Automated Production Line Unveiling: The unveiling of the future automated PCR test kit manufacturing line at the Salt Lake City headquarters will support rapid scaling of diagnostic test production, anticipated to provide efficient testing solutions for Saudi Arabia and 18 other Middle Eastern and North African countries.
- Significance of International Collaboration: CEO Dwight Egan emphasized that international partnerships are crucial for closing the diagnostics gap, showcasing the company's strategy of combining cutting-edge technology with local expertise to enhance diagnostic accessibility in the region.
- AI-Integrated Platform: The Co-Dx PCR platform integrates artificial intelligence and cloud-connected outbreak surveillance capabilities designed for real-time monitoring of infectious disease trends, expected to be a component of the CoMira partnership, reflecting the company's broader strategy of deploying automated, AI-enabled diagnostics infrastructure in key international markets.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Wellgistics Health, Inc. (WGRX) surged 29% to $4.05 in pre-market trading, indicating strong market confidence in its future growth, which may attract more investor interest.
- Other Gainers: Co-Diagnostics, Inc. (CODX) rose 11% to $8.12, while Palladyne AI Corp. (PDYN) increased 10% to $8.21, reflecting an overall positive sentiment in the biotech sector that could drive investment momentum.
- Pre-Market Decliners: AIM ImmunoTech Inc. (AIM) fell 21% to $0.32, highlighting market concerns about its outlook, which may lead investors to reassess their strategies.
- Additional Decliners: BioRestorative Therapies, Inc. (BRTX) dropped 20% to $1.30, and Aditxt, Inc. (ADTX) decreased 18% to $0.17, indicating a lack of confidence in certain biotech companies, potentially impacting their fundraising capabilities.
See More
Co-Diagnostics (CODX) Q4 2025 Earnings Transcript
See More
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
Co-Diagnostics Advances Technology Transfer with CoMira Partnership
- Technology Transfer Initiative: Co-Diagnostics' delegation from CoMira Diagnostics visited the Salt Lake City headquarters, marking a new phase in the planned technology transfer that is expected to enhance diagnostic test production capabilities in Saudi Arabia and 18 other Middle Eastern and North African countries.
- Automated Production Line Unveiling: During the visit, Co-Diagnostics unveiled its future automated PCR test kit manufacturing line, a critical facility that will support rapid scaling of diagnostic test production to meet local healthcare needs and improve operational efficiency.
- Significance of International Collaboration: CEO Dwight Egan emphasized that the partnership with CoMira reflects the belief that closing the diagnostics gap requires a blend of cutting-edge technology and local expertise, aiming to enhance diagnostic accessibility across the region.
- AI-Integrated Platform: The Co-Dx PCR platform integrates artificial intelligence and cloud-connected outbreak surveillance capabilities, which are expected to be part of the CoMira partnership, reflecting the company's strategic intent to deploy automated, AI-driven diagnostic infrastructure in key international markets.
See More
Co-Diagnostics Advances Technology Transfer with CoMira Partnership
- Technology Transfer Initiative: Co-Diagnostics is set to transfer its molecular diagnostics platform and manufacturing capabilities to CoMira Diagnostics in Saudi Arabia, which is expected to significantly enhance diagnostic test production capacity in the region to meet healthcare needs.
- Automated Production Line Unveiling: The unveiling of the future automated PCR test kit manufacturing line at the Salt Lake City headquarters will support rapid scaling of diagnostic test production, anticipated to provide efficient testing solutions for Saudi Arabia and 18 other Middle Eastern and North African countries.
- Significance of International Collaboration: CEO Dwight Egan emphasized that international partnerships are crucial for closing the diagnostics gap, showcasing the company's strategy of combining cutting-edge technology with local expertise to enhance diagnostic accessibility in the region.
- AI-Integrated Platform: The Co-Dx PCR platform integrates artificial intelligence and cloud-connected outbreak surveillance capabilities designed for real-time monitoring of infectious disease trends, expected to be a component of the CoMira partnership, reflecting the company's broader strategy of deploying automated, AI-enabled diagnostics infrastructure in key international markets.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Wellgistics Health, Inc. (WGRX) surged 29% to $4.05 in pre-market trading, indicating strong market confidence in its future growth, which may attract more investor interest.
- Other Gainers: Co-Diagnostics, Inc. (CODX) rose 11% to $8.12, while Palladyne AI Corp. (PDYN) increased 10% to $8.21, reflecting an overall positive sentiment in the biotech sector that could drive investment momentum.
- Pre-Market Decliners: AIM ImmunoTech Inc. (AIM) fell 21% to $0.32, highlighting market concerns about its outlook, which may lead investors to reassess their strategies.
- Additional Decliners: BioRestorative Therapies, Inc. (BRTX) dropped 20% to $1.30, and Aditxt, Inc. (ADTX) decreased 18% to $0.17, indicating a lack of confidence in certain biotech companies, potentially impacting their fundraising capabilities.
See More
Co-Diagnostics (CODX) Q4 2025 Earnings Transcript
See More
Multiple Companies See Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
- NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
- ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
- OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
See More
